Aeterna Zentaris AEZS Stock
Aeterna Zentaris Price Chart
Aeterna Zentaris AEZS Financial and Trading Overview
Aeterna Zentaris stock price | 1.98 USD |
Previous Close | 2.8 USD |
Open | 2.85 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 900 |
Day's Range | 2.71 - 2.85 USD |
52 Week Range | 2.32 - 8.75 USD |
Volume | 8.02K USD |
Avg. Volume | 14.27K USD |
Market Cap | 13.38M USD |
Beta (5Y Monthly) | 1.70707 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.41 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
AEZS Valuation Measures
Enterprise Value | -32753548 USD |
Trailing P/E | N/A |
Forward P/E | -1.0091575 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.1401296 |
Price/Book (mrq) | 0.42866036 |
Enterprise Value/Revenue | -5.24 |
Enterprise Value/EBITDA | 1.955 |
Trading Information
Aeterna Zentaris Stock Price History
Beta (5Y Monthly) | 1.70707 |
52-Week Change | -38.66% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8.75 USD |
52 Week Low | 2.32 USD |
50-Day Moving Average | 2.9 USD |
200-Day Moving Average | 3.44 USD |
AEZS Share Statistics
Avg. Volume (3 month) | 14.27K USD |
Avg. Daily Volume (10-Days) | 12.73K USD |
Shares Outstanding | 4.86M |
Float | 4.85M |
Short Ratio | 8.03 |
% Held by Insiders | 0.45% |
% Held by Institutions | 0.72% |
Shares Short | 81.78K |
Short % of Float | 1.69% |
Short % of Shares Outstanding | 1.67% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -268.29% |
Gross Margin | 98.48% |
EBITDA Margin | -267.97% |
Management Effectiveness
Return on Assets (ttm) | -16.42% |
Return on Equity (ttm) | -57.70% |
Income Statement
Revenue (ttm) | 6.25M USD |
Revenue Per Share (ttm) | 1.29 USD |
Quarterly Revenue Growth (yoy) | 40.30% |
Gross Profit (ttm) | N/A |
EBITDA | -16751000 USD |
Net Income Avi to Common (ttm) | -24342000 USD |
Diluted EPS (ttm) | -4.91 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 46.56M USD |
Total Cash Per Share (mrq) | 9.59 USD |
Total Debt (mrq) | 210K USD |
Total Debt/Equity (mrq) | 0.67 USD |
Current Ratio (mrq) | 7.881 |
Book Value Per Share (mrq) | 6.427 |
Cash Flow Statement
Operating Cash Flow (ttm) | -16280000 USD |
Levered Free Cash Flow (ttm) | -9688375 USD |
Profile of Aeterna Zentaris
Country | United States |
State | SC |
City | Summerville |
Address | 315 Sigma Drive |
ZIP | 29486 |
Phone | (843) 900-3223 |
Website | https://www.zentaris.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Q&A For Aeterna Zentaris Stock
What is a current AEZS stock price?
Aeterna Zentaris AEZS stock price today per share is 1.98 USD.
How to purchase Aeterna Zentaris stock?
You can buy AEZS shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aeterna Zentaris?
The stock symbol or ticker of Aeterna Zentaris is AEZS.
Which industry does the Aeterna Zentaris company belong to?
The Aeterna Zentaris industry is Biotechnology.
How many shares does Aeterna Zentaris have in circulation?
The max supply of Aeterna Zentaris shares is 5.01M.
What is Aeterna Zentaris Price to Earnings Ratio (PE Ratio)?
Aeterna Zentaris PE Ratio is now.
What was Aeterna Zentaris earnings per share over the trailing 12 months (TTM)?
Aeterna Zentaris EPS is -3.41 USD over the trailing 12 months.
Which sector does the Aeterna Zentaris company belong to?
The Aeterna Zentaris sector is Healthcare.
Aeterna Zentaris AEZS included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
- {{ link.label }} {{link}}